Tag Archives: RESI

RESI San Diego: Venture Philanthropy Panel Announcement

18 May

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Investors in venture philanthropy, such as foundations and specific family offices, have deep expertise that is often overlooked. Many venture philanthropic groups have a specific mission in a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

LSN is pleased to announce a panel of five expert venture philanthropic investors for the RESI San Diego Conference on June 19th. The audience will have an exclusive opportunity to hear from:

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals. Be sure not to lose track of the mission in life science, and not miss the opportunity of hearing how these panelists can help you with your philanthropic mission.

Register by Friday to save $200, be the first to request investor meetings on partnering, and hear from this fantastic panel!

Tags: , , , ,

Orphan Drug Investors Share Their Insights at RESI San Diego

11 May

By Lucy Parkinson, Director of Research, LSN

Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.

At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:

Tags: , , , , ,

The Dynamic Landscape of Asia Outbound Dealmaking Comes to RESI

4 May

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

The year 2016 saw strong outbound investments from Asia, with China leading the pack. However, the investment landscape is rapidly changing, influenced by regulatory pressure, political uncertainty, and market demand. For North American entrepreneurs seeking opportunities in Asia, it is critical to understand your counterpart’s strategy and incentives.  Therefore for RESI San Diego, LSN has introduced new panel sessions to the Asia-North America Track in order to highlight the current key players in the region.

China Healthcare Investors

China is clearly a frontrunner in outbound activities. China’s foreign direct investment (FDI) set a record of US$94.2 billion in 2016, up 189% in North America and 90% in Europe, compared to the prior year. Despite the strict currency restrictions implemented by the Chinese government by the end of 2016, this trend is generally expected to continue in the long run.

Among all sectors, healthcare will most likely see sustained growth in investments, fueled by a rapidly aging population and favorable national mandate to upgrade its healthcare industry. The Chinese healthcare sector received 18.3 billion Yuan (US$2.64 billion) in VC investment in 2016, only second to the internet sector. Healthcare VC/PE funds are mushrooming in China in recent years. With sufficient ‘dry powder’ in hand, many fund manager are looking overseas for high-quality, high-return investment targets.

China Strategic Investors

According to PwC, China’s outbound M&A value increased by 246% last year compared to 2015. An increasing number of Chinese pharmaceutical and medical device corporations are scouting around the world for valuable assets. To work with strategic investors, typically overseas partners will have to offer one or more of the following: assets fitting strategically with the Chinese partner’s existing pipeline; critical expertise such as technology platform, production knowhow, and regulatory experience; or access to key markets in the US or Europe.

Korea/Japan Investment Environment

While Chinese outbound deal making is likely to be slowed by tighter currency control, analysts expect Japan’s cash-rich firms to pick up the slack. Many Japanese pharmaceutical companies have already established multinational operations and have participated in overseas venture deals. A weak domestic consumer market and negative interest rates will further drive these corporations to expand businesses offshore.

Following years of government spending in R&D, Korea is experiencing a biotech boom. In 2016, VC investment in Korean biotech surpassed that in IT for the first time. Korean healthcare startups have attracted interest from foreign investment groups and multinational pharma companies. Fueled by the optimistic mood, Korean corporations are now actively engaged in outbound acquisition and expansion.

The week of the BIO event in San Diego sets the perfect stage for cross-border dialogues. The upcoming RESI San Diego conference will include three panels: China Healthcare Investors, China Strategic Partners, and Korea/Japan Investors. Highly experienced deal-makers are invited to share their first-hand experiences and help entrepreneurs understand the nuts and bolts of building a successful collaboration with Asia.

Tags: , ,

RESI San Diego Panel Announcement – Diagnostic Investors

4 May

By Michael Quigley, VP of Market Research, LSN

mike-2

Fundraising for diagnostics companies, like most early stage healthcare technologies, is no easy task. A relative lack of a thriving M&A/IPO exit environment compared to other life science sectors along with high profile flops in the space has made some investors wary. However there exists a significant need for advancement in the field of diagnostics. From pharma companies wanting novel biomarkers to more accurately stratify patients for clinical trials, to the rise of personalized therapies via genomic testing, there’s a growing need for more accurate diagnostics and in many disease areas they do not currently exist.

In addition, many traditionally software or technology focused VCs and major strategics are looking to utilize their expertise to advance bioinformatic breakthroughs. While some these “new” healthcare investors have learned the hard way the difference between healthcare and consumer tech, as they continue to learn they will likely represent an increase of value added capital to the space.

In this session, we will hear from 5 Investors including VCs, large corporations and angels with experience and intent to invest in early stage diagnostics companies. The speakers will cover the types of investments they are looking to make and share insights they have learned working within the space. For any entrepreneur looking to raise capital for a diagnostic technology this is a must attend panel. Look below to see the speakers for yourself. We hope to see you in San Diego.

Tags: , , , , , , ,

Key Stakeholders Share the Value of RESI for Early Stage Investors and Startups

27 Apr

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

In San Diego on June 19th, the Redefining Early Stage Investments (RESI) Conference will bring a new, early stage focused discussion venue for startups and investors who are visiting BIO week and want more opportunities to connect. What makes RESI different? At our last event, RESI on MaRS in Toronto, we asked our key stakeholders this question and here’s what they told us.

Ying Tam – Head of Digital Health – MaRS Discovery District

“All the research says that one of the critical elements for an entrepreneur ecosystem, especially in health, is funding and investment. It takes a long time to nurture a health company, to get it to market and commercialization and scale. So, investment is critical for the development of a startup in health. RESI brings in a whole set of investors from across North America and across the world.”

Rebecca Yu – Head of JLABS @ Toronto – Johnson & Johnson Innovation JLABS

“RESI attracts many repeat attendees, and that speaks to me that there’s a story, there’s something here. There’s great stuff happening here for entrepreneurs. There’s early stage companies from across Canada, from pharmaceuticals to medical devices to consumer health, and of course there’s a big digital health and AI presence here in Toronto. That’s why JLABS and J&J are here. We play in all the sectors, we partner with different groups within this ecosystem, and we see LSN/RESI as a key partner as well, to bring investors to this ecosystem.”

Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec

“The RESI conference is an opportunity to help out these early stage companies such that they can achieve inflection points. If I can identify companies early, then I might become a vendor of choice for them. Getting in early becomes an important objective for me. When I come to a conference like RESI, I come to these early stage companies who are really looking for partnering with investors here, but also get an opportunity to introduce WuXi to them as well.”

RESI attendees can book up to 16 meetings with investors in one day, right at the start of BIO Week. If you want to take this opportunity to start your BIO with a bang, register now.

Tags: , , , , , , ,

RESI San Diego – Early Bird Rate Ends Tomorrow

20 Apr

By Lucy Parkinson, Director of Research, LSN

For the first time, the Redefining Early Stage Investments (RESI) Conference is coming to San Diego, CA. On Monday June 19th, of Bio week, RESI will provide an opportunity to start your week at the Westin San Diego Gaslamp Quarter with up to 16 face to face meetings with the most relevant global investors for your technology. Not only that, but 3 full-day program tracks of investor panels and workshops will help scientist-entrepreneurs learn the ins and outs of early stage fundraising issues.

RESI’s early bird rate ends tomorrow.  If you are headed to BIO and want to achieve maximum ROI on your trip to San Diego, get your RESI pass today.

 

Tags: , ,

RESI San Diego Agenda Announcement

20 Apr

By Michael Quigley, VP of Market Research, LSN

mike-2

For its first trip to San Diego, the Redefining Early Stage Investments (RESI) conference team will be bringing with it a content rich agenda. RESI’s Biotech and Medtech tracks will feature over 75 investor speakers across 16 panels devoted to specific investor types, technology sectors, or new issues in fundraising. Representatives from family offices, big pharma, VC, angels and more will share with the audience the types of opportunities they are currently looking for as well as what it is like to be on the other side of the negotiating table.

RESI’s Early Stage Workshops track features 4 entrepreneur education workshops, including a new session on 505(b)(2) Strategy led by Ken Phelps, CEO of Camargo.

With our Asia-North America Track, one of our newer and most popular additions, attendees will get the chance to hear directly from investors and strategic partners from across the Pacific looking for North American innovation. These panels will be a must-see for any fundraising entrepreneur in the sector.

We are very excited to bring this diverse pool of investors and speakers to San Diego to share their expertise and experience with the hundreds of fundraising scientist-entrepreneurs who attend RESI. While many of our speaking spots are already allocated, if you or someone you know would want to participate please don’t hesitate to reach out.

Tags: , , , ,

← Older Entries
Newer Entries →